ESR1 and breast carcinoma: A study, however, indicated that metformin may enhance ER-negative and tri-negative breast cancer risks in females with type 2 diabetes, despite a possible association between long-term use of metformin and a reduced risk of estrogen receptor (ER)-positive breast cancer in this population [44].